The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

Thinking about what to do with your Daiichi Sankyo Company shares? If you are watching your stocks closely or hunting for opportunities, you have probably noticed this name keeps popping up on analyst ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

Patients were randomized to receive I-DXd 8 or 12 mg/kg intravenously every 3 weeks (Q3W) in part 1 (dose optimization) and received I-DXd 12 mg/kg in part 2 (extension). The primary endpoint was ...

Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio with four late-breaking presentations from more than 20 abstracts at the 2025 ...

AstraZeneca and Daiichi Sankyo are teeing up a TROP2 showdown with Gilead Sciences in first-line triple-negative breast cancer. China's InnoCare Pharma agreed to out-license three autoimmune ...